Drug patent expiry dates aren’t just legal milestones—they’re commercial calendars. Yet most life sciences teams still treat them like a back-office event: track them, file the paperwork, move on. That’s a missed opportunity.
Here’s the agitation: when…

Sell the line before the patent breaks. That’s the uncomfortable truth many pharma equipment suppliers learn too late.
In solid dose manufacturing, the window between “patent still in force” and “generic launch is imminent” is where deals are won—or lo…

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/

The “Smarter Monopoly” Debate Is Here—and It’s About to Shape Drug Prices for Years
Drug innovation is expensive. So are the rules that govern how long companies can recoup that investment. But the conversation is shifting—from the familiar world of st…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologics don’t just “expire.” They cliff.
When a biologic hits Loss of Exclusivity (LOE), the market doesn’t politely wait for your pipel…

Generic competition doesn’t always “end” a drug’s story. Sometimes it just changes the plot.
For patients, generics are the promise of lower prices and broader access. For brand manufacturers, generics are a countdown clock. And in the space between th…

Patients aren’t asking about patents. They’re asking about relief.
If you’ve spent any time around healthcare, you know the real question behind most “drug switching” searches isn’t legal—it’s personal. People type things like “Will this new version …

Evergreening isn’t a surprise—it’s a pattern.
In pharma, the most expensive battles rarely start at the courtroom. They start in the months (or years) before a brand files, when the “next” patent family is quietly assembled, when continuation strategie…

Pfizer’s Keytruda, also known as pembrolizumab, received initial FDA approval on September 4, 2014, for use in treating… https://www.Drugchatter.com/chat/37536/can-you-recall-the-initial-fda-approval-year-for-keytruda/

OpenAI’s “life sciences” pitch is getting louder—and generic drug makers should pay attention.
Because the real story in GPT, Rosalind, and the promise of faster science isn’t just about better models. It’s about what happens when the bottleneck shifts…